EmailWire
12 Jan 2022, 11:32 GMT+10
NEW JERSEY, United States, ROSTOCK, Germany, and BERLIN, Germany - (ARAB NEWSWIRE) - Arcensus, a commercial-stage digital healthcare and diagnostics company that empowers people to take control of their health is pleased to announce that our Founder, Prof. Dr. Arndt Rolfs, a multi-entrepreneur in biotech and former CEO of several innovative biotech companies, including Nasdaq-listed company CENTOGENE, has been appointed as the Chief Executive Officer of Arcensus GmbH.Prof. Rolfs has succeeded the role from Mr. Michael Schlenk and assumed the responsibilities of CEO on January 01, 2022. We are very grateful for the hard work and dedication of Mr. Schlenk for successfully performing the duties of CEO in 2021 and constructing the organization of Arcensus. We are reassured that Mr. Schlenk will continue supporting Arcensus as an active member of our supervisory board.Mr Schlenk wished the new CEO every success: "I wish Arndt and the operational team all the best for 2022. There is no doubt that this year will bring great progress for Arcensus after building the company so successfully in a record time. I look forward to supporting the shaping of the business model as a member of the Supervisory Board."Prof Rolfs is an experienced biotech entrepreneur who knows the necessities and challenges of the healthcare industry very well. Under his leadership, Arcensus will disrupt the genetic diagnostics market through the rapid expansion of its global genomic service and develop new concepts based on genomic knowledge generated worldwide. Arcensus' genomic data already has a diagnostic yield of about 80% in all genetically suspect patients.Prof Rolfs said: "Our expertise in the high-quality interpretation of Whole Genome DNA Sequencing data reflects the next revolution in modern medicine. Our global genomic knowledge will help pharma partners accelerate the development of new drugs, especially for rare diseases."About ArcensusArcensus is a digital healthcare and diagnostics company that empowers people to take control of their health. The company provides a highest-standard, secure, trusted, and comprehensive medical service based on Whole Genome Sequencing. Arcensus analyses the complete genetic information in human DNA and identifies the predispositions as well as reasons for unclear symptoms with the help of cutting-edge technology including artificial intelligence. The detailed medical report suggests better treatment options and helps individuals take preventive measures to live a healthier and longer life.From our offices in New Jersey - United States, Rostock and Berlin - Germany, a cross-functional team of genetic experts, medical doctors, and data scientists works to make the most sophisticated and best genetic interpretation with medical and health prevention applications accessible to everyone.For more information, visit https://arcensus-diagnostics.com/Important Notice and DisclaimerThis press release contains "forward-looking statements" within the meaning of the U.S. federal securities laws. Statements contained herein that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "continues," "expect," "estimate," "intend," "project," and similar expressions and future or conditional verbs such as "will," "would," "should," "could," "might," "can," and "may," are generally intended to identify forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Arcensus' actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, negative worldwide economic conditions and ongoing instability and volatility in the worldwide financial markets, the effects of the COVID-19 pandemic on our business and results of operations, possible changes in current and proposed legislation, regulations and governmental policies, pressures from increasing competition and consolidation in our industry, the expense and uncertainty of regulatory approval, including from the U.S. Food and Drug Administration, our reliance on third parties and collaboration partners, including our ability to manage growth and enter into new client relationships, our dependency on the rare disease industry, our ability to manage international expansion, our reliance on key personnel, our reliance on intellectual property protection, fluctuations of our operating results due to the effect of exchange rates, our ability to streamline cash usage, our requirement for additional financing and our ability to continue as a going concern, or other factors.Media Contact:
Arcensus GmbH
Awais Bhatti
+49 1525 7692031
Get a daily dose of Middle East Star news through our daily email, its complimentary and keeps you fully up to date with world and business news as well.
Publish news of your business, community or sports group, personnel appointments, major event and more by submitting a news release to Middle East Star.
More InformationMumbai (Maharashtra) [India], May 3 (ANI): In a major leap towards empowering India's Animation, Visual Effects, Gaming, Comics and...
With global markets disrupted by geopolitical tensions, trade wars, Indias 2025 energy policy shows a clear shift toward stability...
Mayor of Brussels Philippe Close dressed up as a giant panda attends a reception of a Chinese lantern exhibition in Brussels, Belgium,...
Abu Dhabi [UAE], May 3 (ANI/WAM): Under the patronage of Sheikh Mansour bin Zayed Al Nahyan, Vice President, Deputy Prime Minister,...
New Delhi [India], May 3 (ANI): The Indian rupee is likely to trade with an appreciating bias in the near term, supported by a mix...
Amaravati (Andhra Pradesh) [India] May 2 (ANI): In a historic step toward India's technological future, Andhra Pradesh Chief Minister...
SYDNEY, NSW, Australia - The Australian Labor Party has been swept to victory for a second term after defeating the Coalition in an...
WASHINGTON, D.C.: The U.S. State Department has started a second round of its deferred resignation program, according to an internal...
WASHINGTON, D.C.: U.S. President Donald Trump said this week that some fraud cases had been reported to the Justice Department based...
NEW YORK CITY, New York: This week, the Trump administration has approved an emergency rule that allows gas stations across the U.S....
WASHINGTON, D.C.: Major automobile companies want Congress to stop California's plan to ban the sale of gas-only cars by 2035—a rule...
Drones have struck a ship on a mission to highlight the halting of humanitarian aid to the blockaded Gaza Strip, triggering a fire....